ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2186

Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis

Wei-Hsuan Lo-Ciganic1, Lysbeth Floden2, Erin L. Ashbeck3, Lili Zhou1 and C. Kent Kwoh3,4, 1Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, 2Department Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, 3The University of Arizona Arthritis Center, Tucson, AZ, 4Rheumatology, University of Arizona, College of Medicine, Tucson, AZ

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: analgesics, Anti-depressant, opioids, osteoarthritis and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Epidemiology and Public Health - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Analgesics including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and nutraceuticals are commonly used for pain relief in osteoarthritis (OA). Although it has been reported that opioids and some antidepressants may increase the risk of falls, results from studies assessing the association between analgesic use and falls are mixed. Prior studies were limited by focusing on a single fall as the outcome, and lack of adjusting for pain severity, concurrent use of other medications associated with falls (e.g., anticholinergics), and other potential confounders. Our objective was to assess the association between type of analgesic use and subsequent risk of falls among participants with or at risk of knee OA.

Methods:  We performed a longitudinal analysis with 4 years of follow-up (n=4,511) from the Osteoarthritis Initiative (OAI) cohort study. Analgesic use was identified through medication inventory and/or questionnaires. We grouped patients into 6 exclusive subgroups based on annually assessed analgesic use in the following hierarchical order of potency: (1) opioids, (2) antidepressants, (3) prescription NSAIDs, (4) over-the counter (OTC) NSAIDs/aspirin and other pain medications, (5) nutraceuticals, and (6) no analgesic use. We used multivariate logistic regression with generalized estimating equations to estimate the effect of analgesic use on the subsequent risk of any fall and recurrent falls in the following year, adjusted for sociodemographics, health status/behavior (e.g., pain severity, concurrent use of other medications related to falls), and access-to-care factors.

Results:  Overall analgesic use decreased from 64.8% at baseline to 52.8% at the 4-year follow-up visit. In contrast, opioid use increased from 2.9% to 3.5% over this same time period. In each annual follow-up period, approximately 33% of participants self-reported at least one occurrence of a fall and 15% reported recurrent falls (i.e.≥ 2). Compared to those without any analgesic use, participants in the opioid and antidepressant groups had modest increased odds of both any fall (opioids: adjusted OR [aOR]: 1.37, 95% CI 1.08-1.74; antidepressants: aOR=1.27, 95% CI: 1.09-1.48) and recurrent falls (opioids: aOR: 1.34, 95% CI 1.00-1.80; antidepressants: aOR=1.34, 95% CI: 1.10-1.64; Table 1). Participants in the OTC NSAIDs/other pain medications group had a 24% higher odds of recurrent falls.

Conclusion:  Opioids and antidepressants were associated with a modest increased risk of both any fall and recurrent falls after adjustment for pain severity and other potential confounders, among participants with or at risk of knee OA. Clinical management of pain with opioids and antidepressants among those at risk of falling warrants caution. Future research is needed to exmine and better understand the association between risk of falls and the use of OTC NSAIDs/other pain medications.

Table 1. Multivariate models of analgesic use and subsequent risk of falls

aOR*

(95% CI)

Any falls    
No pain medications

1.00

reference

Opioids

1.37

(1.08, 1.74)

Antidepressants

1.27

(1.09, 1.48)

Prescription NSAIDs

1.08

(0.93, 1.25)

Over-the-counter NSAIDs and other pain medications

1.13

(0.99, 1.28)

Nutraceuticals

1.08

(0.95, 1.24)

Recurrent falls

 

 

No pain medications

1.00

reference

Opioids

1.34

(1.00, 1.80)

Antidepressants

1.34

(1.10, 1.64)

Prescription NSAIDs

1.10

(0.89, 1.35)

Over-the-counter NSAIDs and other pain medications

1.24

(1.05, 1.47)

Nutraceuticals

1.19

(0.99, 1.42)

Abbreviations: NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio, CI: Confidence Interval *Multivariate models were adjusted for sociodemographics (age, sex, race, marital status, education), time-varying health status/behavior (Charlson’s comorbidity index, history of knee surgery, depression, BMI, K/L grade, WOMAC total scores, KOOS symptom subscale, pain severity, Short Form-12 health survey, anticholinergic, diuretic, and muscle relaxant use), and access to health care factors (i.e., health insurance coverage, annual household income).

Disclosure: W. H. Lo-Ciganic, None; L. Floden, None; E. L. Ashbeck, None; L. Zhou, None; C. K. Kwoh, None.

To cite this abstract in AMA style:

Lo-Ciganic WH, Floden L, Ashbeck EL, Zhou L, Kwoh CK. Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/analgesic-use-and-subsequent-risk-of-falls-in-participants-with-or-at-risk-of-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analgesic-use-and-subsequent-risk-of-falls-in-participants-with-or-at-risk-of-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology